公开(公告)号：US20190292191A1

公开(公告)日：2019-09-26

申请号：US16314574

申请日：2016-06-23

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： John V. Duncia ,  Daniel S. Gardner ,  John Hynes ,  John E. Macor ,  Natesan Murugesan ,  Joseph B. Santella ,  Hong Wu ,  Durgarao Kantheti ,  Satheesh Kesavan Nair ,  Venkatram Reddy Paidi ,  Sreekantha Ratna Kumar ,  Kandhasamy Sarkunam ,  Ramesh Kumar Sistla ,  Subba Rao Polimera

IPC: C07D487/04 ,  C07D471/04 ,  C07D413/04 ,  C07D401/14

Abstract: Disclosed are compounds of Formula (I) Formula (I) or salts thereof, wherein HET is a heteroaryl selected from oxazolyl, pyrazolyl, imidazo[1,2-b]pyridazin-3-yl, and pyrazolo[1,5-a]pyrimidin-3-yl, wherein said heteroaryl is attached to the pyridinyl group in the compound of Formula (I) by a carbon ring atom in the heteroaryl and wherein said heteroaryl is substituted with zero to 2 Rb; and R1, R3, and Rb are define herein. Also disclosed are methods of using such compounds as modulators of IRAK4, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing inflammatory and autoimmune diseases, or in the treatment of cancer.